Caught Out By PI Industries' 54% Fall? Here's What Bears Saw

If you had looked at PI Industries in late 2025 and decided to sit it out, the last twelve months might feel like risk accidentally avoided rather than missed opportunity. Investors who held PI Industries over the past year are down 53.6%, including dividends. That is a harsh outcome. The question is not who got lucky. It is which assumptions on growth, margins, or regulatory risk were already on the table that you could have stress tested upfront.

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

The easy part of this move is behind PI Industries. Zero in on 225 high quality undervalued stocks for companies trading below our estimates.

The Argument You Would Have Been Weighing Up On PI Industries

The shares cost ₹3,749 at the start of the period, and PI Industries sat between two very different stories that both sounded reasonable.

On the bullish side, the Narrative put Fair Value at ₹4,062 and leaned on 12.0% revenue growth with profit margins settling near 19.9%, helped by new launches across agchem, pharma, electronics, and biologicals.

The bearish view anchored Fair Value at ₹2,800 and focused on tighter regulation and supply issues, with an assumption that margins would compress toward 16.8% as traditional agrochemicals faced pressure.

What The Results Changed For PI Industries

Pioxaniliprole, the first indigenously discovered insecticide molecule from PI Industries, supported the bullish idea that R&D could widen the product base. Yet the Q2 2027 figures told a different story. Revenue moved from ₹18,723m in Q2 2026 to ₹17,018m, while net income slid from ₹4,093m to ₹1,222m and net margin fell from 21.9% to 7.2%. The evidence supported the cautious case.

The episode turned on one assumption: that higher margin businesses would offset regulatory and product pressure. When you review another stock, compare that claim with reported net margin over several periods and check whether new launches appear in both revenue and profitability.

What You Are Paying For In PI Industries Today

PI Industries now trades at ₹1,735, after a 53.6% loss over the past year. The selected Narrative sees Fair Value above that level and leans on the idea that newer pharma, biologicals and electronics activities can reshape earnings quality.

A buyer today would be assuming that current upfront losses in these businesses turn into profitable, scaled operations that support stronger group margins.

"Key Takeaways: Bullish analysts expect PI Industries to use its expanding pharma, biologicals and global client relationships to build on its existing profitability and strengthen high-margin, recurring revenue streams over time. The main thing that has to go right is that PI Industries turns the current upfront investments and EBITDA losses in pharma and global biologicals into profitable, scaled businesses while continuing to fund R&D and capacity."

One Narrative disagrees with today's price. → See where this Narrative says PI Industries should trade

Looking One Step Beyond PI

PI Industries is about chemistry and protection on the farm. Your next question could be where those crops eventually pull demand.

Electrification needs far more raw material for power lines, motors and storage. That creates a different kind of pinch point in the background.

One global miner is spending heavily to lift production of copper, aluminum and lithium. It is trying to tie that effort to disciplined costs and project timing.

If that shift holds, the same electrification trend worrying agchem demand could be shaping a very different type of earnings mix elsewhere.

One Narrative has already put a figure on it. → Uncover the company trading 17% below one Narrative's Fair Value

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com